Clinical trials: in Croatia
Symptomatic Paroxysmal Atrial Fibrillation Without Clinically Significant Heart Diseases
Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation
The purpose of this study is to evaluate the effectiveness of Pulmonary Vein Isolation (PVI) performed with the Arctic Front™ Advance Cardiac CryoAblation Catheter System as first-line therapy in comparison with antiarrhythmic…
- Trial name
- NCT01803438
- Testing
- cryoballoon ablation system, Antiarrhythmic Drugs
- Where
- 19 sites in Argentina, Australia and 7 more
- Volunteers
- 220 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
COVID-19 Acute Respiratory Distress Syndrome, Viral Disease
Registry for Hemoperfusion of Covid-19 ICU Patients
The ongoing COVID-19 pandemic caused high hospitalization and mortality rates especially in critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on…
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Viral Disease, Critical Illness, Multi Organ Failure
- Trial name
- HERICC (NCT05470907)
- Testing
- Hemoperfusion
- Where
- Croatia
- Volunteers
- 1,050 people
- Sponsor
- Croatian Society for Organ Support
Peripheral Arterial Disease, Peripheral Vascular Diseases
BOLT Lithotripsy RESTORE ATK Trial
The RESTORE (ATK) above the knee study is a prospective, non- randomized, multi-center study for treatment of stenotic lesions with the Bolt Intravascular Lithotripsy System.
- Trial name
- RESTORE ATK (NCT05662787)
- Testing
- Intravascular Lithotripsy
- Where
- 11 sites in Austria, Croatia and 1 more
- Volunteers
- 97 people
- Sponsor
- Bolt Medical
Crohn's Disease, Colitis
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to…
- Conditions
- Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
- Trial name
- NCT01369355
- Testing
- Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
- Where
- 220 sites in United States, Australia and 24 more
- Volunteers
- 1,282 people
- Sponsor
- Janssen Research & Development, LLC
First Line Non-Small Cell Lung Cancer
Avelumab in First-line NSCLC (JAVELIN Lung 100)
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in…
- Trial name
- NCT02576574
- Testing
- Avelumab, Pemetrexed, Paclitaxel
- Where
- 349 sites in United States, Australia and 40 more
- Volunteers
- 1,214 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Breast Cancer
The OPBC-07/microNAC Study
The aim of this multicenter retrospective cohort study is to determine the safety of omission of axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy.
- Trial name
- NCT06529302
- Where
- 84 sites in United States, Argentina and 28 more
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Basel, Switzerland
Liver Diseases
Population-based Study in Screening for Liver Fibrosis
Study to assess the prevalence of significant liver fibrosis in general population using Transient Elastography
- Trial name
- LiverScreen (NCT03789825)
- Where
- 45 sites in Croatia, Denmark and 7 more
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- Judit Pich Martínez
Ulcerative Colitis (UC)
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the…
- Trial name
- NCT03398148
- Testing
- risankizumab IV, risankizumab SC
- Where
- 430 sites in United States, Argentina and 42 more
- Volunteers
- 1,558 people
- Sponsor
- AbbVie
Hemophilia A, Hemophilia B
An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog Alfa
The goal of this low-interventional study is to describe the overall joint health in patients with haemophilia A or haemophilia B prophylactically treated with rFVIIIFc or rFIXFc.
- Trial name
- JOIN-us (NCT05856266)
- Testing
- Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US), Haemophilia Joint Health Score (HJHS)
- Where
- 56 sites in Bulgaria, Croatia and 9 more
- Volunteers
- 10 people
- Sponsor
- Swedish Orphan Biovitrum
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS.
- Trial name
- NCT03085810
- Testing
- Ocrelizumab
- Where
- 193 sites in United States, Argentina and 27 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Atopic Dermatitis
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046.
- Trial name
- NCT04195698
- Testing
- Upadacitinib
- Where
- 116 sites in United States, Australia and 20 more
- Volunteers
- 475 people
- Sponsor
- AbbVie
DCIS, Breast Carcinoma in Situ
The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS
The study hypothesis is that the rate of inadequate surgical margins after conservative breast surgery for DICS and the rate of reoperation (re-excision or/and mastectomy) is lower in the group of patients who underwent standard…
- Conditions
- DCIS, Breast Carcinoma in Situ, Calcification
- Trial name
- CEMinDCIS (NCT06217458)
- Testing
- Contrast Enhanced Mammography
- Where
- Croatia
- Volunteers
- 100 people
- Sponsor
- Clinical Hospital Center Rijeka
Medullary Thyroid Cancer
Predictive Factors for Medullary Thyroid Cancer Aggressiveness
This study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.
- Trial name
- MYELO (NCT06292988)
- Testing
- Total Thyroidectomy
- Where
- 46 sites in United States, Austria and 22 more
- Volunteers
- 500 people
- Sponsor
- Aristotle University Of Thessaloniki
Excess Skin of Both Eyelids, Contrast Sensitivity
The Effect of Upper Blepharoplasty on Vision Quality in the Early Postoperative Period
Contrast sensitivity (CS) and tear film (TF) changes are noted in late postoperative period after upper blepharoplasty (UB), while the same was rarely investigated in the early postoperative period.
- Conditions
- Excess Skin of Both Eyelids, Contrast Sensitivity, Tear Film Insufficiency of Both Eyes, Corneal Topography
- Trial name
- NCT05549713
- Testing
- Upper blepharoplasty
- Where
- Croatia
- Volunteers
- 40 people
- Sponsor
- Osijek University Hospital
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
- Trial name
- VIVID-1 (NCT03926130)
- Testing
- Mirikizumab, Ustekinumab
- Where
- 580 sites in United States, Argentina and 32 more
- Volunteers
- 1,158 people
- Sponsor
- Eli Lilly and Company
Neuromyelitis Optica Spectrum Disorder
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of…
- Trial name
- NCT04660539
- Testing
- satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF)
- Where
- 53 sites in United States, Bulgaria and 16 more
- Volunteers
- 119 people
- Sponsor
- Hoffmann-La Roche
Opioid Use, Pain, Chronic
Pain AND Opioids After Surgery
The aim of this study is to document the perioperative opioid use and its safety in the UK and countries in Europe and to describe its association with surgical complications, persistent pain and quality of life.
- Conditions
- Opioid Use, Pain, Chronic, Pain, Postoperative, Quality of Life
- Trial name
- PANDOS (NCT05877157)
- Where
- 4 sites in Croatia, United Kingdom
- Volunteers
- 10,000 people
- Sponsor
- University of Aberdeen
Rhegmatogenous Retinal Detachment
Comparison of Anatomical and Functional Outcomes of Laser Photocoagulation and Cryopexy in Patients with Rhegmatogenous Retinal Detachment Treated with Pneumatic Retinopexy
Rhegmatogenous Retinal Detachment is a pathological condition in which the inner layers of the retina separate from its outermost layer due to fluid entering between these layers through a retinal tear.
- Trial name
- NCT06694259
- Testing
- Pneumatic retinopexy with transscleral cryopexy, Pneumatic retinopexy with laser photocoagulation
- Where
- Croatia
- Volunteers
- 40 people
- Sponsor
- Clinical Hospital Center, Split
Schizophrenia
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with schizophrenia. Participants in the study will receive the drug being studied.
- Trial name
- NCT04109950
- Testing
- SEP-363856
- Where
- 78 sites in United States, Bulgaria and 6 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.